Onconova Therapeutics Inc represents values of innovation, dedication to improving cancer treatments, and commitment to patient care. The company's corporate philosophy revolves around developing novel therapeutics to address unmet medical needs and enhancing the overall quality of life for cancer patients. With a focus on targeted therapies and precision medicine, Onconova Therapeutics Inc aims to revolutionize cancer treatment through groundbreaking research and clinical advancements. The company's strong belief in scientific excellence, collaboration with key stakeholders, and a patient-centric approach drives its pursuit of transforming the landscape of cancer care.

Onconova Therapeutics Inc is primarily present in the United States.

Onconova Therapeutics Inc has achieved significant milestones in its journey. The company obtained Fast Track designation from the U.S. FDA for its drug rigosertib, which is being developed to treat Myelodysplastic Syndromes and pancreatic cancer. Onconova also conducted a pivotal Phase 3 ONTIME trial for rigosertib in patients with Myelodysplastic Syndromes, reaching its primary endpoint. Additionally, the company successfully completed its Phase 2 trial of Oral Rigosertib in combination with Azacitidine for Myelodysplastic Syndromes. These accomplishments demonstrate Onconova's commitment to advancing innovative therapies and improving treatment options for patients.

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of cancer. Founded in 1998, the company is headquartered in Newtown, Pennsylvania. Onconova is dedicated to discovering and advancing innovative molecules that target critical cellular pathways involved in cancer progression. Its lead product candidate, Rigosertib, is being evaluated in various clinical trials for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other solid tumors. Onconova Therapeutics Inc has established strategic collaborations with global pharmaceutical companies for the development and commercialization of its pipeline.

The main competitors of Onconova Therapeutics Inc in the market include pharmaceutical companies such as Novartis, Pfizer, and Merck. These companies, like Onconova Therapeutics Inc, operate in the biotechnology sector, focusing on the development and commercialization of innovative therapies for various diseases, particularly cancer. The competition among these industry players leads to a dynamic market landscape where each company strives to bring forth groundbreaking treatments and gain a competitive edge in the field.

Onconova Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Onconova Therapeutics Inc revolves around developing and commercializing novel therapies for cancer through targeted intervention at the cellular level. They focus on discovering and developing small molecules that target key cellular pathways involved in cancer progression. By advancing their pipeline of drug candidates, Onconova aims to provide innovative treatment options for patients battling various types of cancer. They employ a research-driven approach to identify and validate potential therapeutic targets, followed by rigorous clinical development and regulatory processes. Onconova Therapeutics Inc strives to improve patient outcomes and address unmet medical needs in the oncology field.

Коефициентът на цена спрямо печалбата (КЦП) на Onconova Therapeutics е -6,16.

Коефициентът на цена към оборот (KUV) на Onconova Therapeutics е 438,03.

AlleAktien качественият резултат за Onconova Therapeutics е 2/10.

очаквана Onconova Therapeutics оборотът е 265 200,00 USD.

очаквана Onconova Therapeutics печалба е -18,85 млн. USD.

Onconova Therapeutics Inc is a biopharmaceutical company that develops innovative drugs for the treatment of cancer and chronic bone marrow diseases. It is headquartered in Newtown, Pennsylvania, and also has branches in Germany and India. The business model of Onconova Therapeutics is based on the joint development of innovative drugs for the treatment of serious diseases in close collaboration with partner companies and research institutions. The company follows a customized drug development approach, offering a wide range of tailored drugs that can be ordered by customers depending on their specific medical needs. Onconova Therapeutics is divided into two business segments: the Oncology segment and the Onconova-assisted Research segment. In the Oncology segment, the company focuses on the development of drugs for the treatment of solid tumors and hematological cancers. This includes ongoing research programs that specifically target innovative drug candidates. Onconova-assisted Research was established as a research initiative that invests in innovative technologies for medical development in various disease areas. This initiative provides support for customer development programs that want to leverage the progress of Onconova Therapeutics to advance their own drug candidates in clinical trials. Onconova Therapeutics also offers a range of products, including Rigors Stimulator (a chemical-free technology for generating early warning signals for infections) and OTP201 (a substance developed for use in combination cancer chemotherapy). The company has achieved several key milestones, including completing funding rounds, establishing partnerships with pharmaceutical companies (such as Teva Pharmaceuticals Industries Ltd), and obtaining patents for its core competencies. In terms of operational results, Onconova Therapeutics showed strong financial performance in 2019, with a 45 percent increase in cash balance compared to the previous year. The company has focused on expanding into new markets in Europe and Asia and believes this will contribute to consistent growth. Overall, Onconova Therapeutics offers a wide portfolio of innovative drugs and technologies for the treatment of cancer and bone diseases. The company is dedicated to customized drug development and strives to meet the diverse needs of its customers. With the continuation of its research initiative and the expansion into new markets in Europe and Asia, Onconova Therapeutics is well positioned to remain innovative and promote the growth of the company in the coming years.

Onconova Therapeutics разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Onconova Therapeutics в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Onconova Therapeutics е US68232V4059.

WKN на Onconova Therapeutics е A2N6RH.

Тикерът на Onconova Therapeutics е ONTX.

През последните 12 месеца Onconova Therapeutics изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Onconova Therapeutics да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Onconova Therapeutics в момента е .

Onconova Therapeutics изплаща дивидент на тримесечие. Той се разпределя в месеците .

Onconova Therapeutics платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Onconova Therapeutics се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Onconova Therapeutics на 6.10.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 6.10.2024 г..

Последното дивидентно плащане беше извършено на 6.10.2024 г..

През година 2023 Onconova Therapeutics изплати 0 USD под формата на дивиденти.

Дивидентите от Onconova Therapeutics се изплащат в USD.